Search results for "From ACP Diabetes Monthly"
Incretin-based drugs not associated with any increase in risk for pancreatic diseases | ACP Gastroenterology Monthly
The findings may reassure prescribers of dipeptidyl peptidase-4 inhibitors that the drug class does not significantly increase the risk of adverse pancreatic outcomes compared with other second-line therapies, study authors said.
ACP Gastroenterology Monthly
ACP Gastroenterology Monthly delivers a monthly summary of news in gastroenterology and hepatology, including the latest research, clinical guidelines, and FDA drug actions.
Metformin use associated with improved outcomes in patients with historical contraindications | ACP Gastroenterology Monthly
Metformin appears to improve certain outcomes in patients with moderate chronic kidney disease, congestive heart failure, or chronic liver disease with hepatic impairment, according to a recent systematic review.
January 27, 2017 | ACP Gastroenterology Monthly
ACP Gastroenterology Monthly delivers a monthly summary of news in gastroenterology and hepatology, including the latest research, clinical guidelines, and FDA drug actions.